A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

NCT07518043 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal and/or Cardia Cancer
Melanoma
Urothelial Carcinoma (UC)

Interventions

DRUG: HLX18
DRUG: OPDIVO®

Sponsor

Shanghai Henlius Biotech